金融界消息 截至2025年8月5日收盘，丰原药业（000153）报收于7.38元，上涨0.54%，换手率6.45%， 成交量29.23万手，成交金额2.16亿元。 资金流向方面，今日主力资金净流出1553.27万元，占比成交额7.2%。其中，超大单净流出193.46万 元、占成交额0.9%，大单净流出1359.81万元、占成交额6.3%，中单净流出流出467.59万元、占成交额 2.17%，小单净流入2020.85万元、占成交额9.36%。 丰原药业最新一期业绩显示，截至2025一季报，公司营业总收入9.41亿元、同比减少16.05%，归属净利 润3802.08万元，同比减少19.12%，扣非净利润3352.73万元，同比减少19.55%，流动比率0.933、速动比 率0.657、资产负债率56.43%。 天眼查商业履历信息显示，安徽丰原药业股份有限公司，成立于1997年，位于芜湖市，是一家以从事医 药制造业为主的企业。企业注册资本46477.3722万人民币，实缴资本3670.6137万人民币。公司法定代表 人为汝添乐。 通过天眼查大数据分析，安徽丰原药业股份有限公司共对外投资了20家企业，参与招投标项目2 ...

Group 1 - The stock price of Fengyuan Pharmaceutical closed at 7.50 yuan on July 29, 2025, down 1.45% from the previous trading day, with a trading range of 8.94% [1] - The company is primarily engaged in the research, production, and sales of chemical raw materials and formulations, covering various therapeutic areas including antipyretic analgesics, antibiotics, and vitamins [1] - As a key enterprise in the pharmaceutical industry of Anhui Province, Fengyuan Pharmaceutical's business involves multiple segments including raw materials, formulations, and pharmaceutical commerce [1] Group 2 - On July 29, the stock experienced significant volatility, with a drop of over 2% within 5 minutes around 9:35 AM, followed by a rebound of over 2% shortly after at 9:41 AM, indicating active market trading [1] - The net outflow of main funds was 21.79 million yuan, accounting for 0.64% of the circulating market value, suggesting a certain degree of capital withdrawal [1]

通过天眼查大数据分析，安徽丰原药业股份有限公司共对外投资了20家企业，参与招投标项目237次， 知识产权方面有商标信息79条，专利信息51条，此外企业还拥有行政许可328个。 来源：金融界 丰原药业最新一期业绩显示，截至2025一季报，公司营业总收入9.41亿元、同比减少16.05%，归属净利 润3802.08万元，同比减少19.12%，扣非净利润3352.73万元，同比减少19.55%，流动比率0.933、速动比 率0.657、资产负债率56.43%。 天眼查商业履历信息显示，安徽丰原药业股份有限公司，成立于1997年，位于芜湖市，是一家以从事医 药制造业为主的企业。企业注册资本46477.3722万人民币，实缴资本3670.6137万人民币。公司法定代表 人为汝添乐。 金融界消息 截至2025年7月29日收盘，丰原药业（000153）报收于7.5元，下跌1.45%，换手率24.86%， 成交量112.58万手，成交金额8.65亿元。 资金流向方面，今日主力资金净流出2178.83万元，占比成交额2.52%。其中，超大单净流出6119.80万 元、占成交额7.08%，大单净流入3940.97万元、占成交额4 ...

Group 1 - The vitamin sector has seen a rise of 2.34%, ranking 9th among concept sectors, with 62 stocks increasing in value [1][2] - Notable gainers include Nonnawell, Fengyuan Pharmaceutical, and Nengte Technology, which reached the daily limit, while Minsheng Health, Zhenhua Co., and Erkang Pharmaceutical also showed significant increases of 8.75%, 7.15%, and 6.69% respectively [1][2] - The sector experienced a net inflow of 5.92 billion yuan from main funds, with 43 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2][3] Group 2 - The top stocks by net inflow include Nonnawell with 925.69 million yuan, followed by Fengyuan Pharmaceutical with 884.21 million yuan, and Zhongsheng Pharmaceutical with 728.46 million yuan [2][3] - The net inflow ratios for Fengyuan Pharmaceutical, Nengte Technology, and Huate Dain are 24.78%, 19.08%, and 14.28% respectively, indicating strong investor interest [3] - Stocks such as Dongbao Biological, Huate Dain, and Huaheng Biological experienced declines of 3.71%, 2.04%, and 0.91% respectively, highlighting some volatility within the sector [1][5]

Core Viewpoint - The concept of generic drug consistency evaluation has seen a rise of 2.73%, ranking fifth among concept sectors, with significant inflows of capital into various stocks within this sector [1][2]. Group 1: Market Performance - As of July 1, the generic drug consistency evaluation concept experienced a 2.73% increase, with 120 stocks rising, including top performers like Fengyuan Pharmaceutical, Guizhou Bailing, and Anglikang, which hit the daily limit [1]. - The leading gainers in this sector included Yuekang Pharmaceutical (up 15.55%), Yipinhong (up 14.72%), and Hongri Pharmaceutical (up 8.13%) [1][2]. - Conversely, the stocks with the largest declines were Yiming Pharmaceutical, Yongtai Technology, and *ST Suwu, which fell by 2.16%, 1.71%, and 0.79% respectively [1]. Group 2: Capital Inflows - The generic drug consistency evaluation sector attracted a net inflow of 829 million yuan, with 74 stocks receiving capital inflows, and 13 stocks seeing over 50 million yuan in net inflows [2]. - The stock with the highest net inflow was Yipinhong, which saw 168 million yuan, followed by Guizhou Bailing and Huahai Pharmaceutical with net inflows of 158 million yuan and 135 million yuan respectively [2][3]. - The top three stocks by net inflow ratio were Fengyuan Pharmaceutical (24.78%), Guizhou Bailing (17.80%), and Huahai Pharmaceutical (14.87%) [3]. Group 3: Stock Performance Metrics - Yipinhong had a daily increase of 14.72% with a turnover rate of 5.65% and a net capital flow of approximately 168 million yuan [3]. - Guizhou Bailing increased by 10.04% with a turnover rate of 13.11% and a net capital flow of about 158 million yuan [3]. - Huahai Pharmaceutical rose by 5.74% with a turnover rate of 3.26% and a net capital flow of around 135 million yuan [3].

Core Viewpoint - Anhui Fengyuan Pharmaceutical Co., Ltd. has announced its profit distribution plan for the year 2024, which includes a cash dividend of 1 RMB per 10 shares, approved by the shareholders' meeting held on May 6, 2025 [1][2]. Summary by Sections Profit Distribution Plan - The company plans to distribute a cash dividend of 1 RMB (including tax) for every 10 shares based on a total share capital of 464,773,722 shares as of December 31, 2024 [1]. Implementation of the Distribution - The cash dividend distribution will be executed as follows: for every 10 shares, a cash dividend of 1 RMB will be paid to all shareholders. For overseas institutions and certain individual shareholders, the dividend will be 0.9 RMB per 10 shares due to tax considerations [1]. - The tax treatment for individual shareholders varies based on the holding period of the shares, with specific tax rates applied for different durations [1]. Key Dates - The record date for the distribution is set for May 29, 2025, and the ex-dividend date is May 30, 2025 [1][2]. Distribution Recipients - The recipients of the dividend will be all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shenzhen Branch, as of the record date [2]. Consultation Information - The company has provided contact details for inquiries regarding the dividend distribution, including a contact person and phone numbers [2].

股票简称：丰原药业 股票代码：000153 公告编号：2025-024 安徽丰原药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 安徽丰原药业股份有限公司（下称"公司"或"本公司"）2024 年度利润分配方 案已获 2025 年 5 月 6 日召开的公司 2024 年度股东大会审议通过，现将本次权益分 派实施事宜公告如下： 一、股东大会审议通过利润分配方案等情况 1、公司 2024 年度利润分配方案已获公司 2024 年度股东大会审议通过。本公司 2024 年度利润分配预案如下： 公司董事会拟定 2024 年度的利润分配预案为：以 2024 年 12 月 31 日公司总股 本 464,773,722 股为基数，向全体股东按每 10 股派发现金红利 1 元（含税），不实施 公积金转增股本。 2、自本次利润分配方案披露至实施期间公司股本总额未发生变化。 3、本次实施的分配方案与公司 2024 年度股东大会审议通过的利润分配方案一 致。 4、本次实施分配方案距离股东大会审议通过的时间未超过两个月。 5、本次分配按分配 ...

Group 1 - The sugar substitute concept declined by 0.82%, ranking among the top declines in the concept sector, with companies like Baolingbao, Bailong Chuangyuan, and Chenguang Biotech experiencing significant drops [1][2] - Among the sugar substitute stocks, 8 saw price increases, with Zhonghua International, Luxin Investment, and Xinghu Technology rising by 1.37%, 1.34%, and 1.09% respectively [1][2] - The sugar substitute sector experienced a net outflow of 118 million yuan, with 17 stocks seeing net outflows, and 5 stocks with outflows exceeding 10 million yuan, led by Jinhai Biological with a net outflow of 44.98 million yuan [2][3] Group 2 - The top net inflow stocks in the sugar substitute sector included Jinhai Industrial, Rhine Biological, and Shengquan Group, with net inflows of 16.36 million yuan, 12.29 million yuan, and 5.05 million yuan respectively [2][3] - The outflow leaderboard for the sugar substitute sector featured Jinhai Biological, Yasheng Group, and Baolingbao, with respective outflows of 44.98 million yuan, 25.20 million yuan, and 22.92 million yuan [2][3] - The trading activity in the sugar substitute sector showed varied turnover rates, with Baolingbao at 14.36% and Jinhai Biological at 6.48% [2][3]

安徽丰原药业股份有限公司 章 程 （经公司 2025 年第一次临时股东大会审议通过） 二○二五年五月八日 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 3 | | | 第二节 | 股份增减和回购 4 | | | 第三节 | 股份转让 5 | | | | 第四章股东和股东大会 | 5 | | 第一节 | 股东 5 | | | 第二节 | 股东大会的一般规定 7 | | | 第三节 | 股东大会的召集 9 | | | 第四节 | 股东大会的提案与通知 10 | | | 第五节 | 股东大会的召开 11 | | | 第六节 | 股东大会的表决和决议 14 | | | 第五章 | 董事会 | 17 | | 第一节 | 董事 18 | | | 第二节 | 董事会 20 | | | 第六章 | 经理及其他高级管理人员 | 23 | | 第七章 | 监事会 | 24 | | 第一节 | 监事 24 | | | 第二节 | 监事会 25 | | | 第八章 | 财务会计制度、利润分配和审计 | ...

安徽丰原药业股份有限公司董事会议事规则 （经 2025 年 5 月 8 日公司 2025 年第一次临时股东大会审议通过） 第一章 总则 第一条 为规范安徽丰原药业股份有限公司（以下简称"公司"）董事会行为，确 保董事会公平、公正、高效运作和科学决策的职能，根据《中华人民共和国公司法》 （以下简称《公司法）》、《中华人民共和国证券法》（以下简称《证券法》）及《安徽 丰原药业股份有限公司章程》（以下简称《公司章程》）和其他有关规定，特制定本 议事规则。 第二条 董事会是公司的常设机构，是公司的经营决策和业务领导机构，是股东 大会决议的执行机构，对股东大会负责，由股东大会选举产生，依照《公司章程》 的规定行使职权。 第二章 董事职责 第三条 公司董事为自然人，有下列情形之一的，不能担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产或者破坏社会主义市场经济秩序，被判处刑罚， 执行期满未逾 5 年，或者因犯罪被剥夺政治权利，执行期满未逾 5 年； （三）担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企业的 破产负有个人责任的，自该公司、企业破产清算完结之日起未逾 3 年 ...